- Diagnostics
- Thursday, 25 Jun 2020
New Noninvasive Nutritional Testing with Metabolomix+
Genova Diagnostics introduces a new collect-at-home nutritional test to help support telemedicine practices and provide clinicians a more comprehensive set of options without a blood draw. The Metabolomix+ profile is a unique combination of nutritional tests that assess the functional need for antioxidants, B-vitamins, minerals, digestive support and amino acids with add-on modules based on a patient's unique needs. Add-on modules include bloodspot essential and metabolic fatty acids, toxic and nutrient elements, as well as genomics.
The Metabolomix+ profile identifies complex nutritional insufficiencies that may underlie chronic conditions and helps inform a treatment plan to optimize health outcomes. Testing can assist in evaluation of many areas including fatigue, mood disorders, dietary guidance, athletic performance, weight loss and digestive complaints.
Chief Scientific Officer, Dr. Amy Peace Brewer shared, "The study of metabolomics is all encompassing - organic acids, amino acids, fatty acids, stool metabolites, hormone metabolites, and more. Genova Diagnostics has been an industry leader in metabolomic testing for decades. Our newest profile, Metabolomix+, is a modular profile allowing clinicians to build their own version of metabolomic testing based on clinical need. As an added benefit, it can be collected in the comfort of the patient's home, at their convenience."
Related Industry Updates
QiSant™ Initial Publication Demonstrates Strong Clinical Validation of Urine-Based Assay in Kidney Transplant Surveillance
Mar 19, 2020
Allergy Treatment Progress in Regeneron’s Immunology Pipeline
Feb 11, 2026
United Global Alliance Partners With Acumen Research Laboratories to Distribute Novel Coronavirus Diagnostic Test Kits
Apr 07, 2020
Yuyu Pharma will export COVID-19 test sets from SD BIOSENSOR to the world market
Jun 18, 2020
Asia Pacific Animal Health Market Outlook, Research, Trends and Forecast up to 2027| Virbac, Elanco, Merck & co
Oct 22, 2020
FDA Approves Diffusion-Weighted Images for Elekta Unity, Expanding Options for Assessment During Therapy
Dec 16, 2019
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
May 26, 2020